Lilly reports good results for brain-cancer drug

Eli Lilly reports its new cancer drug enzastaurin was able to shrink brain tumors in up to 25% of patients in a trial and stopped tumor growth in another 10%. The drug, which Lilly hopes to get to the market by 2008, cuts off drug supply to tumors and disrupts cell pathway signaling that is vital to tumor cells' survival.

View Full Article in:

Indianapolis Star (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Fort Worth, TX
Senior Scientist - Cell Engineering Group
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC